Quantcast

Stocks Showing Rising Market Leadership: Supernus Pharmaceuticals Earns 81 RS Rating


Shutterstock photo

When putting together your watch list, look for stocks with an 80 or higher RS Rating . Supernus Pharmaceuticals ( SUPN ) now meets that criteria, with a jump from 78 to 81 Friday.

[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.

History reveals that the market's biggest winners typically have an RS Rating of at least 80 in the early stages of their moves.

Looking For Winning Stocks? Try This Simple Routine

Supernus Pharmaceuticals is building a consolidation with a 50.14 entry . See if it can clear the breakout price in heavy volume.

The company reported -28% earnings growth in its most recent report. Revenue increased 42%.

Supernus Pharmaceuticals holds the No. 69 rank among its peers in the Medical-Biomed/Biotech industry group. Bioverativ ( BIVV ), Corcept Therapeutics ( CORT ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Rising Relative Strength?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: SUPN , CORT , LGND



More from Investor's Business Daily

Subscribe






Investor's Business Daily
Contributor:

Investor's Business Daily

Investing










Research Brokers before you trade

Want to trade FX?